The global hepatic encephalopathy drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The market growth is majorly attributed owing to the increasing R&D activities as well as clinical trials for hepatic encephalopathy drugs. For instance, in 2018, Norgine B.V. announced positive results for the clinical trial, which was conducted for testing the safety and efficacy of rifaximin in liver cirrhosis and chronic hepatic encephalopathy. As per this trial, rifaximin-? reduced systemic inflammation, immune dysfunction, and infection susceptibility in patients suffering from liver cirrhosis. 

Based on the geography, North America is anticipated to hold a substantial share in the global hepatic encephalopathy drugs market during the forecast period, owing to the increasing prevalence of hepatic encephalopathy in this region. For instance, according to National Center for Biotechnology Information (NCBI), in September 2020, around 7-11 million cases of hepatic encephalopathy were prevalent in the US, with around 150,000 patients being newly diagnosed each year. Out of the newly diagnosed patients, around 20% have liver cirrhosis, and almost 60% of patients suffer from chronic hepatitis C either alone or along with the alcohol-related liver disease. Moreover, symptoms of hepatic encephalopathy are observed in around 70% of patients with liver cirrhosis.

Some key players operating in the market include Lupin Ltd., Bausch Health Companies Inc., and Mallinckrodt LLC, among others. The market players are focusing on strengthening their position in the market by adopting various strategies such as mergers and acquisitions, partnerships and collaborations, new product launches and development in the existing product portfolio, and so on. For instance, in April 2020, Umecrine Cognition AB, a Karolinska Development portfolio company, reported positive results for a phase II clinical trial for the drug candidate golexanolone, which was tested on patients with the risk of developing hepatic encephalopathy.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape:  Lupin Ltd., Bausch Health Companies Inc., and Mallinckrodt LLC, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Hepatic Encephalopathy Drugs  Market Report by Segment

By Drug Class

• Antibiotics

• L-Ornithine L-Aspartate

• Laxatives

• Others

By Route of Administration

• Oral

• Intravenous

• Rectal

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

Global Hepatic Encephalopathy Drugs  Market by Region